This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Varenicline Effects In Schizophrenic Smokers

This study has been completed.
University of Illinois at Chicago
Information provided by (Responsible Party):
Robert C. Smith MD PhD, Nathan Kline Institute for Psychiatric Research Identifier:
First received: October 22, 2007
Last updated: August 2, 2017
Last verified: August 2017
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) effects nicotinic binding to leukocytes and DNMT1 mRNA in lymphocytes. Patients are assessed on subjective and objective measures of smoking , selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline ( 1-3 mg/day).

Condition Intervention Phase
Schizophrenia Tobocco Use Disorder Nicotine Dependance Drug: Varenicline Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking

Resource links provided by NLM:

Further study details as provided by Robert C. Smith MD PhD, Nathan Kline Institute for Psychiatric Research:

Primary Outcome Measures:
  • Self Report of Smoking [ Time Frame: Baseline and during 2 months of treatment ]
    Patients self-report of smoking cigarettes

  • CO Breathalyzer Level [ Time Frame: baseline and during 2 months of treatment ]
  • Plasma Cotinine [ Time Frame: baseline 1 month and 2 months ]
    cotinine level in plasma ng/ml.

Secondary Outcome Measures:
  • RBANS Neuropsychological Battery [ Time Frame: baseline and month 2 of treatment ]
    The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measures cognitive function in patients with schizophrenia. RBANS scores for list learning range from 0 to 40. RBANS Index scores for visual-spatial index, language index, and Total score range from 40-160. Higher scores on all these measures indicate better performance or better cognitive ability.

  • Change From Baseline in Psychiatric Symptoms [ Time Frame: Baseline and 2 months later ]
    The Positive and Negative Syndrome Scale (PANSS) was used to measure psychiatric symptoms. Item scores ranged from 1 (Absent) to 6 (Severe) for symptoms on the Positive Scale (total subscale range: 7-42), the Negative Scale (total subscale range: 7-42), and the General Psychopathology Scale (total subscale range:16-96). All three subscales were summed for the PANSS total score (total scale range: 30-180). Higher numbers indicate more psychopathology. Therefore, if scores are reduced at post-baseline ratings, this would indicate lower psychopathology.

Enrollment: 14
Study Start Date: June 2007
Study Completion Date: December 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: varenciline
open label varenicline 2mg/day
Drug: Varenicline
Varenicline 1-2 mg/day
Other Name: Chantix


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis
  • Recent History of Cigarette smoking
  • Ages 18-65
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00548470

United States, New York
Manhattan Psychatirc Center
New York, New York, United States, 10035
Sponsors and Collaborators
Nathan Kline Institute for Psychiatric Research
University of Illinois at Chicago
Principal Investigator: Robert C Smith, MD, PhD Nathan Kline insitutue fo Psychiatric Research; NYU School of Medicine
  More Information

Responsible Party: Robert C. Smith MD PhD, Researchy Pasychiatrist, : Prinicipla Investigator, Nathan Kline Institute for Psychiatric Research Identifier: NCT00548470     History of Changes
Other Study ID Numbers: 06I/C34-0
Study First Received: October 22, 2007
Results First Received: December 17, 2016
Last Updated: August 2, 2017

Keywords provided by Robert C. Smith MD PhD, Nathan Kline Institute for Psychiatric Research:
cigarette smoking

Additional relevant MeSH terms:
Tobacco Use Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 21, 2017